Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Consultant Physician, Mashhad University of Medical Sciences, Mashhad, Iran.
Asian Pac J Cancer Prev. 2023 May 1;24(5):1507-1511. doi: 10.31557/APJCP.2023.24.5.1507.
Currently, there is no standard of treatment for the management of the recurrent high-grade glioma. Re-resection, re-irradiation, and chemotherapy are among main treatment options without any proven efficacy.
To compare the outcome of second line treatment of recurrent high-grade glioma by re-irradiation or bevacizumab-based chemotherapy.
Retrospectively, patients with the recurrent high-grade glioma treated by re-irradiation (ReRT group) (34 patients) or bevacizumab-based chemotherapy (Bev group) (40 patients) as the first-file after the first recurrence were compared in term of first-line progression free survival (PFS), second-line PFS, and overall survival (OS).
Both groups were similar in term of gender (p=0.859), age (=0.071), type of first-line treatment (p=0.227), and performance status (p=0.150). With a median follow-up of 31 months (m), mortality rate was 41.2% and 70% in the ReRT and Bev groups, respectively. In the Bev and ReRT groups, median OS was 27 m (95% confidence interval (CI) 20-33.9 m) vs. 132 m (95% CI 52.9-211 m) (p<0.0001), median first-line PFS was 11 m (95% CI 7.14-28.7 m) vs. 37 m (95% CI 8.42-65.75 m) (p<0.0001), and median second-line PFS was 7 m (95% CI 3.9-10 m) vs. 9 m (95% CI 5.5-12.4 m) (p=0.564), respectively.
The PFS is similar after the second line treatment of recurrent primary central nervous system malignancies either by re-irradiation or bevacizumab-based chemotherapy.
目前，对于复发性高级别胶质瘤的治疗尚无标准方案。再次手术切除、再放疗和化疗是主要的治疗选择，但均未被证实有效。
比较复发性高级别胶质瘤二线治疗中再放疗或贝伐珠单抗为基础的化疗的疗效。
回顾性分析首次复发后行再放疗（ReRT 组）（34 例）或贝伐珠单抗为基础的化疗（Bev 组）（40 例）作为一线治疗的复发性高级别胶质瘤患者的二线无进展生存期（PFS）、总生存期（OS）。
两组患者在性别（p=0.859）、年龄（p=0.071）、一线治疗类型（p=0.227）和功能状态（p=0.150）方面无差异。中位随访 31 个月时，ReRT 组和 Bev 组的死亡率分别为 41.2%和 70%。Bev 组和 ReRT 组的中位 OS 分别为 27 个月（95%置信区间[CI] 20-33.9 个月）和 132 个月（95%CI 52.9-211 个月）（p<0.0001），中位一线 PFS 分别为 11 个月（95%CI 7.14-28.7 个月）和 37 个月（95%CI 8.42-65.75 个月）（p<0.0001），中位二线 PFS 分别为 7 个月（95%CI 3.9-10 个月）和 9 个月（95%CI 5.5-12.4 个月）（p=0.564）。
复发性原发性中枢神经系统恶性肿瘤二线治疗后，再放疗或贝伐珠单抗为基础的化疗的 PFS 相似。
